About sonoma pharmaceuticals - SNOA
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. Its products are used for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.
SNOA At a Glance
Sonoma Pharmaceuticals, Inc.
5445 Conestoga Court
Boulder, Colorado 80301
| Phone | 1-800-759-9305 | Revenue | 14.29M | |
| Industry | Pharmaceuticals: Major | Net Income | -3,457,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 12.195% | |
| Fiscal Year-end | 03 / 2026 | Employees | 168 | |
| View SEC Filings |
SNOA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.19 |
| Price to Book Ratio | 0.811 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.658 |
| Enterprise Value to Sales | -0.165 |
| Total Debt to Enterprise Value | -0.13 |
SNOA Efficiency
| Revenue/Employee | 85,047.619 |
| Income Per Employee | -20,577.381 |
| Receivables Turnover | 6.401 |
| Total Asset Turnover | 0.996 |
SNOA Liquidity
| Current Ratio | 3.036 |
| Quick Ratio | 2.324 |
| Cash Ratio | 1.312 |
SNOA Profitability
| Gross Margin | 38.249 |
| Operating Margin | -25.966 |
| Pretax Margin | -20.346 |
| Net Margin | -24.195 |
| Return on Assets | -24.101 |
| Return on Equity | -65.548 |
| Return on Total Capital | -73.304 |
| Return on Invested Capital | -64.847 |
SNOA Capital Structure
| Total Debt to Total Equity | 6.915 |
| Total Debt to Total Capital | 6.467 |
| Total Debt to Total Assets | 2.211 |
| Long-Term Debt to Equity | 0.612 |
| Long-Term Debt to Total Capital | 0.573 |